Literature DB >> 8442668

Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus.

K P Vatsis1, W W Weber.   

Abstract

The human N-acetylation polymorphism is a genetic trait phenotypically reflected by differences in N-acetyltransferase (NAT) activity with therapeutic agents (rapid and slow acetylation), but a genetic invariability in N-acetylation of some arylamine drugs is also known. There are two highly similar human NAT genes: NAT1 is thought to encode a genetically invariant protein, whereas NAT2 has conclusively been shown to represent a polymorphic locus. This study demonstrates the presence of discrete NAT1 structural variants among Caucasians. These were detected by direct sequencing of 1.6-kilobase NAT1 fragments generated by the polymerase chain reaction with liver and leukocyte DNA from 13 subjects of established acetylator phenotype and NAT2 genotype. A prominent alteration in one of the variants was obliteration of the consensus polyadenylation signal (AATAAA-->AAAAAA). Several mutations were discernible in all regions of the second variant allele, including silent (codon 153) and nonsilent (Ser-214-->Ala) substitutions in the coding region and deletion of nine bases from an AT-rich segment in the 3' untranslated region. One-half of the unrelated subjects were either homozygous or heterozygous for the mutant NAT1 alleles, both of which obeyed a Mendelian inheritance pattern. These novel results unambiguously show that human NAT1, like NAT2, is a polymorphic locus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8442668     DOI: 10.1006/abbi.1993.1116

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  24 in total

1.  N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism.

Authors:  S P Spielberg
Journal:  J Pharmacokinet Biopharm       Date:  1996-10

2.  NATb/NAT1*4 promotes greater arylamine N-acetyltransferase 1 mediated DNA adducts and mutations than NATa/NAT1*4 following exposure to 4-aminobiphenyl.

Authors:  Lori M Millner; Mark A Doll; Jian Cai; J Christopher States; David W Hein
Journal:  Mol Carcinog       Date:  2011-08-11       Impact factor: 4.784

3.  Antioxidant enzymes, presbycusis, and ethnic variability.

Authors:  Anthony Bared; Xiaomei Ouyang; Simon Angeli; Li Lin Du; Kimberly Hoang; Denise Yan; Xue Zhong Liu
Journal:  Otolaryngol Head Neck Surg       Date:  2010-08       Impact factor: 3.497

Review 4.  The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance.

Authors:  Ahmed A Abulfathi; Peter R Donald; Kim Adams; Elin M Svensson; Andreas H Diacon; Helmuth Reuter
Journal:  Br J Clin Pharmacol       Date:  2020-06-21       Impact factor: 4.335

Review 5.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

6.  N-acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancers with chromosome 8p deletions.

Authors:  A L Hubbard; D J Harrison; C Moyes; A H Wyllie; C Cunningham; E Mannion; C A Smith
Journal:  Gut       Date:  1997-08       Impact factor: 23.059

7.  Characterization of a hormone response element in the mouse N-acetyltransferase 2 (Nat2*) promoter.

Authors:  L Estrada-Rodgers; G N Levy; W W Weber
Journal:  Gene Expr       Date:  1998

8.  Chromosomal localization of human genes for arylamine N-acetyltransferase.

Authors:  D Hickman; A Risch; V Buckle; N K Spurr; S J Jeremiah; A McCarthy; E Sim
Journal:  Biochem J       Date:  1994-02-01       Impact factor: 3.857

9.  Arylamine N-acetyltransferase in Balb/c mice: identification of a novel mouse isoenzyme by cloning and expression in vitro.

Authors:  S L Kelly; E Sim
Journal:  Biochem J       Date:  1994-09-01       Impact factor: 3.857

10.  Pharmacokinetics of a novel N-methyl-D-aspartate receptor antagonist (SM-18400): identification of an N-acetylated metabolite and pre-clinical assessment of N-acetylation polymorphism.

Authors:  Masashi Yabuki; Yutaka Kon-Ya; Masaki Kataoka; Takeshi Shimizudani; Kyoko Akao; Masaki Ito; Hiroshi Kanamaru; Iwao Nakatsuka
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jan-Mar       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.